Dalton Venture Wins Eight Awards from Joy List, Touzijia and Qimingpian for Biotech, AI Medical Breakthroughs, Innovative Devices, Life Sciences, Best Early-Stage Investment Institution and Healthcare Investment Institution

道彤投资·September 8, 2026·0·3

Recently, the winners of three major rankings were announced: the 10th Healthcare Investment Excellence Awards, the **Touzijia** 2025–2026 Fund Partner Rankings, and the Qimingpian 2026 Mid-Year China Equity Investment Rankings. Across the three lists, **Ning Huang, founding partner of Dalton Venture, was named to the Best Early-Stage Investor TOP 25, while Dalton Venture was recognized as Best Biotech Investment Firm, Best AI Healthcare Breakthrough Investment Firm, Best Innovative Medical Devices and Life Sciences Investment Firm, and...

Honor Express

Honor

The 10th Healthcare Investment Excellence Awards, the Touzijia 2025-2026 Fund Partner Rankings, and the Qimingpian 2026 Mid-Year China Equity Investment Rankings were recently announced. Across the three rankings, Dalton Venture Founding Partner Ning Huang was named to the Best Early-Stage Investors TOP25, and Dalton Venture collected eight awards in total, including Best Biotech Investment Firm, Best AI Healthcare Breakthrough Investment Firm, Best Innovative Devices & Life Sciences Investment Firm, Best Early-Stage Investment Firm TOP30, Healthcare Sector Investment Firm TOP10, China's Most Active Early-Stage Investment Firms TOP40, and China's Best Early-Stage Investment Firms (Comprehensive) TOP40.

Produced by HaoYue Capital, the flagship "Healthcare Investment Excellence Awards" adheres to principles of fairness, impartiality, openness, and neutrality, evaluating investment firms across multiple dimensions: deal activity in healthcare, transaction capacity, investment returns, and post-investment value creation for portfolio companies. On the strength of its professional investment capabilities and outstanding track record, Dalton Venture was named "Best Biotech Investment Firm," "Best AI Healthcare Breakthrough Investment Firm," and "Best Innovative Devices & Life Sciences Investment Firm" in this ranking. Dalton Family portfolio companies also received honors — Rhino Health was named "Best Innovative Devices & Life Sciences Company of the Year," and Shuimu Molecule was named "Best AI Healthcare Breakthrough Company of the Year."

Dalton Venture

Best Biotech Investment Firm

Dalton Venture

Best AI Healthcare Breakthrough Investment Firm

Dalton Venture

Best Innovative Devices & Life Sciences Investment Firm

Rhino Health

Best Innovative Devices & Life Sciences Company of the Year

Shuimu Molecule

Best AI Healthcare Breakthrough Company of the Year

Over the past year, China's equity investment industry has undergone a deep restructuring and redefinition of value. Standing at the starting point of a new cycle, Touzijia and its research arm, the Touzijia Research Institute, have officially released the "2025-2026 Fund Partner Rankings." Dalton Venture was named to the "2025-2026 Best Early-Stage Investment Firms TOP30," and Dalton Venture Founding Partner Ning Huang was named to the "2025-2026 Best Early-Stage Investors TOP25."

Dalton Venture

2025-2026 Best Early-Stage Investment Firms TOP30

Ning Huang of Dalton Venture

2025-2026 Best Early-Stage Investors TOP25

On August 25, the Qimingpian 2026 Mid-Year China Equity Investment Rankings were released. The rankings treat data as the first principle of selection, evaluating performance across the four dimensions of fundraising, investing, managing, and exiting. Dalton Venture received three honors: "Healthcare Sector Investment Firms TOP10," "Most Active Early-Stage Investment Firms TOP40," and "Best Early-Stage Investment Firms (Comprehensive) TOP40."

Dalton Venture

Healthcare Sector Investment Firms TOP10

Dalton Venture

Most Active Early-Stage Investment Firms TOP40

Dalton Venture

Best Early-Stage Investment Firms (Comprehensive) TOP40

Like-minded and steady on the long road ahead, Dalton has grown into a leading domestic industrial investment firm, with deep, systematic positions and investments across medical devices and equipment, brain-computer interfaces, biomanufacturing, Embodied Artificial Intelligence, and new materials — along with a strong track record and numerous success stories. As an early- to mid-stage investor, we are gratified to see the value that persistence creates: multiple innovative technology investments made early on have now come to fruition, and several of these projects represent national firsts in scientific and technological achievement.

Going forward, Dalton Venture will continue to deepen its expertise, stay the course, and help more outstanding companies achieve leapfrog growth — creating value for the progress and development of the healthcare industry.

END